Navigation Links
NxStage to Present at the JPMorgan Healthcare Conference
Date:12/16/2008

LAWRENCE, Mass.Dec. 16 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that Jeffrey H. Burbank, Chief Executive Officer and Robert Brown, Chief Financial Officer, will be presenting at the JPMorgan Healthcare Conference on Wednesday, January 14, 2009 at the Westin St. Francis Hotel in San Francisco.

NxStage's investor presentation is scheduled for Wednesday, January 14th at 4:30 p.m. PT. To listen to the audio webcast of the presentation during the event, please visit: http://www.nxstage.com and click on 'Investor Information'.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Examples of these forward-looking statements include statements as to Messrs. Burbank and Brown's plans to present at this conference. NxStage specifically disclaims any obligation to update these forward-looking statements. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.

    Contact:
    Kristen K. Sheppard, Esq.
    Investor Relations
    ksheppard@nxstage.com


'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NxStage Medical to Present at the Thomas Weisel Partners Healthcare Conference on September 5, 2007
2. NxStage Medical Provides Update on Medisystems Acquisition
3. NxStage(R) Medical to Report Third Quarter 2007 Financial Results on Friday, November 2nd
4. Arbios Announces SEPET(TM) Manufacturing Agreement With NxStage Medical
5. NxStage Medical to Present at the Piper Jaffray Healthcare Conference on November 27, 2007
6. NxStage Medical Announces Needle Supply Agreement with DaVita
7. NxStage Appoints Tom Shea as Senior Vice President of Manufacturing Operations
8. NxStage Medical to Present at William Blair Growth Stock Conference
9. NxStage Announces Access to Demographic and Outcomes Information for the Growing U.S. Daily Home Hemodialysis Patient Population
10. NxStage Announces Investor Conference Schedule
11. NxStage Medical to Present at JMP Securities Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... UAS ... the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The company, ... proud to add Target to its list of well-respected retailers. This list includes ...
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
(Date:6/23/2016)...   EpiBiome , a precision microbiome engineering company, ... financing from Silicon Valley Bank (SVB). The financing will ... its drug development efforts, as well as purchase additional ... has been an incredible strategic partner to us – ... would provide," said Dr. Aeron Tynes Hammack , ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:5/24/2016)... Calif. , May 24, 2016 Ampronix facilitates superior patient care by ... LMD3251MT  3D medical LCD display is the latest premium product recently added to the ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... when it comes to expanding freedom for high net ... Even in today,s globally connected world, there is ... conferencing system could ever duplicate sealing your deal with ... obtaining second passports by taking advantage of citizenship via ...
Breaking Biology News(10 mins):